Neuroone Medical Technologies (NMTC) Capital Expenditures (2019 - 2026)

Neuroone Medical Technologies has disclosed Capital Expenditures across 8 years of filings, most recently posting $38516.0 for Q1 2026.

• Quarterly Capital Expenditures rose 1114.63% year-over-year to $38516.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133425.0 (up 68.27% YoY) and the FY2025 annual result came in at $81742.0, down 31.99% from the prior year.
• Capital Expenditures slipped to $38516.0 in Q1 2026, from $40754.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $175694.0 in Q1 2023 and bottomed at $3171.0 in Q1 2025.
• The 5-year median for Capital Expenditures is $38516.0 (2026), against an average of $51709.5.
• Year-over-year, Capital Expenditures tumbled 89.89% in 2025 and soared 1114.63% in 2026.
• Neuroone Medical Technologies' Capital Expenditures stood at $11512.0 in 2022, then surged by 222.54% to $37131.0 in 2023, then plunged by 34.24% to $24416.0 in 2024, then surged by 66.92% to $40754.0 in 2025, then dropped by 5.49% to $38516.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $38516.0, $40754.0, and $10607.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.